Adenoma formation by ingenol 3,5,20-triacetate.
Twice weekly i.p. administration of ingenol 3,5,20-triacetate in phosphate buffer saline (PBS), to a group of female NMRI mice, initiated topically with DMBA in acetone, developed no skin tumor, but produced high incidence of adenomas.
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000008:administration & dosage; D000236:Adenoma / Q000139:chemically induced*; D000287:Administration, Topical; D000818:Animals; D001551:Benz(a)Anthracenes / Q000008:administration & dosage; D002273:Carcinogens; D003043:Cocarcinogenesis; D004224:Diterpenes / Q000633:toxicity*; D005260:Female; D007274:Injections, Intraperitoneal; D008175:Lung Neoplasms / Q000139:chemically induced*; D051379:Mice
D001551:Benz(a)Anthracenes; D002273:Carcinogens; D004224:Diterpenes; C027280:ingenol-3,5,20-triacetate; D015127:9,10-Dimethyl-1,2-benzanthracene